Italian intersociety consensus on DOAC use in internal medicine

摘要: The direct oral anticoagulants (DOACs) are drugs used in clinical practice since 2009 for the prevention of stroke or systemic embolism non-valvular atrial fibrillation, and treatment secondary venous thromboembolism. four DOACs, including three factor Xa inhibitors (rivaroxaban, apixaban edoxaban) one thrombin inhibitor (dabigatran) provide anticoagulation therapy alternatives to Vitamin K antagonists (VKAs). Despite their clear advantages, DOACs require on part internist a thorough knowledge pharmacokinetic pharmacodynamic characteristics ensure correct use, laboratory monitoring appropriate management adverse events. This document represents consensus paper use by representatives Italian scientific societies: Society Internal Medicine (SIMI), Federation Associations Hospital Managers (FADOI), Study Haemostasis Thrombosis (SISET). formulates expert opinion guidance pragmatic managing, reversing anticoagulant effect both chronic emergency settings. practical may help create adequate protocols patients hospitalized ion internal medicine wards, where often elderly subjects affected poly-morbidities renal insufficiency, and, thus, particular attention drug–drug interactions peri-procedural protocols.